Dokument: Der Einfluss von Anämie auf den zirkulierenden NO-Pool im akuten Koronarsyndrom
| Titel: | Der Einfluss von Anämie auf den zirkulierenden NO-Pool im akuten Koronarsyndrom | |||||||
| Weiterer Titel: | The Effect of Anemia on the Circulating NO Pool in Acute Coronary Syndrome | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=74604 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20261001-174911-5 | |||||||
| Kollektion: | Dissertationen | |||||||
| Sprache: | Deutsch | |||||||
| Dokumententyp: | Wissenschaftliche Abschlussarbeiten » Dissertation | |||||||
| Medientyp: | Text | |||||||
| Autor: | Jäger, Lilly-Christin [Autor] | |||||||
| Dateien: |
| |||||||
| Beitragende: | Univ. Prof. Dr. Kelm, Malte [Gutachter] Prof. Dr. med. Germing, Ulrich [Gutachter] | |||||||
| Stichwörter: | Anemia, ACS, NO, Nitrit, Nitrat, eNOS | |||||||
| Dokumententyp (erweitert): | Dissertation | |||||||
| Dewey Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit | |||||||
| Beschreibungen: | Zusammenfassung (deutsch)
Rationale: Herzkreislauferkrankungen, insbesondere ischämische Herzerkrankungen, stellen die häufigsten Todesursachen in der westlichen Welt dar. Eine Anämie tritt häufig bei Patienten mit ST-Hebungsinfarkt auf und beeinflusst hier die Prognose negativ. Der Einfluss der endothelialen Stickstoffmonoxidsynthetase (eNOS), des Stickstoffmonoxids (NO) selbst und des NO-Speichermetaboliten ist in diesem Zusammenhang bisher nicht abschließend geklärt. Zielsetzung: Ziel dieser Arbeit war es, den Einfluss einer Anämie auf den akuten Myokardinfarkt zu quantifizieren. Insbesondere sollten die Auswirkungen eines akuten Myokardinfarktes auf den NO-Pool und wiederum die Auswirkungen einer Anämie im akuten Myokardinfarkt auf den NO-Pool untersucht werden. Hypothese: Wir stellten die Hypothese auf, dass eine Anämie im akuten Myokardinfarkt mit einer Reduktion der NO-Metabolite vor allem in den roten Blutkörperchen einhergeht. Aufgrund dessen verlieren die roten Blutkörperchen ihre kardioprotektiven Eigenschaften und werden dysfunktional. Dieser Pathomechanismus könnte Einfluss auf die erhöhte Mortalität von anämischen Patienten im akuten Myokardinfarkt haben. Methoden und Resultate: Zur Bestimmung des NO-Pools wurden Blutproben von Patienten mit einer koronaren Herzerkrankung und akutem ST-Hebungsinfarkt asserviert und diese jeweils in Subgruppen mit Anämie und ohne Anämie unterteilt. Anhand der Blutproben bestimmten wir die NO-Metabolite Nitrit und nitryliserte Spezies mittels reduktiver Gasphasenchemilumineszenz. Des Weiteren wurde Nitrat mittels ENO im Plasma und Erythrozyten bestimmt. Bei Patienten mit akutem Myokardinfarkt und Anämie zeigten sich deutlich verringerte Nitrit- und Nitratwerte in Erythrozyten. Patienten mit chronischer KHK und Anämie zeigten keine verminderten Nitrit- und Nitratwerte in Erythrozyten. Schlussfolgerungen: Zusammenfassend lässt sich sagen, dass eine normozytäre, normochrome Anämie im akuten Myokardinfarkt zu einer Reduktion der NO-Metabolite in Erythrozyten führt. Dies liefert Hinweise auf einen gestörten NO-Metabolismus, der ursächlich für die erhöhte Mortalität von Patienten mit Anämie und akutem Myokardinfarkt sein könnte. Erythrozyten von anämischen Patienten zeigen verringerte kardioprotektive Eigenschaften, welches sich auf eine RBC Dysfunktionalität zurückführen lässt.Summary (english) Rationale: Cardiovascular diseases, especially ischemic heart disease, are the most common cause of death in the Western world. Anemia often occurs in patients with ST-elevation myocardial infarction and harms prognosis. In this context, the influence of endothelial nitric oxide synthase (eNOS), nitric oxide (NO) itself, and NO storage metabolites has not yet been conclusively clarified. Objective: The aim of this study was to quantify the influence of anemia on acute myocardial infarction. In particular, the effects of acute myocardial infarction on the NO pool and, in turn, the effects of anemia in acute myocardial infarction on the NO pool were to be investigated. Hypothesis: We hypothesized that anemia in acute myocardial infarction is associated with a reduction in NO metabolites, especially in red blood cells. As a result, red blood cells lose their cardioprotective properties and become dysfunctional. This pathomechanism could influence the increased mortality of anemic patients in acute myocardial infarction. Methods and results: To determine the NO pool, blood samples were collected from patients with coronary artery disease (CAD), and acute ST-elevation myocardial infarction, which were than divided into subgroups with and without anemia. Using the blood samples, we determined the NO metabolites nitrite and nitrile-reactive species by reductive gas phase chemiluminescence. Nitrate was determined by using ENO in plasma and erythrocytes. Patients with acute myocardial infarction and anemia showed significantly reduced nitrite and nitrate levels in erythrocytes. Patients with chronic CHD and anemia did not show reduced nitrite and nitrate levels in erythrocytes. Conclusions: In Conclusion, normocytic, normochromic anemia in acute myocardial infarction leads to a reduction in NO metabolites in erythrocytes. This provides evidence of impaired NO metabolism, which could be the cause of increased mortality in patients with anemia and acute myocardial infarction. Erythrocytes from anemic patients show reduced cardioprotective properties, which may be due to dysfunction. | |||||||
| Quelle: | 1. (Destatis), S.B., Todesursachen in Deutschland 2023. 2024.
2. (ZI), Z.d.k.r.B., Versorgungsatlas – Dashboard häufige chronische Krankheiten. 2023.
3. Gosswald, A., et al., [Prevalence of myocardial infarction and coronary heart disease in adults aged 40-79 years in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013. 56(5-6): p. 650-5.
4. Bundesärztekammer (BÄK), K.r.B.K., Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Nationale VersorgungsLeitlinie Chronische KHK. 2024. Langfassung, Version 7.0.
5. Watanabe, T., et al., Atherosclerosis and macrophages. Acta Pathol Jpn, 1989. 39(8): p. 473-86.
6. Bennett, M.R., S. Sinha, and G.K. Owens, Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res, 2016. 118(4): p. 692-702.
7. Geng, Y.J. and P. Libby, Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol, 2002. 22(9): p. 1370-80.
8. Hoffmann, U., T.J. Brady, and J. Muller, Cardiology patient page. Use of new imaging techniques to screen for coronary artery disease. Circulation, 2003. 108(8): p. e50-3.
9. Ehara, S., et al., Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation, 2004. 110(22): p. 3424-9.
10. Beckman, J.A., et al., Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol, 2001. 21(10): p. 1618-22.
11. Vink, A., et al., Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors? J Am Coll Cardiol, 2001. 38(3): p. 718-23.
12. Schaar, J.A., et al., Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J, 2004. 25(12): p. 1077-82.
13. Society, C.C., Grading of angina pectoris. Circulation, 1976. 54:522-3.
14. Neumann, J.T., et al., Temporal trends in incidence and outcome of acute coronary syndrome. Clin Res Cardiol, 2020. 109(9): p. 1186-1192.
15. Thygesen, K., et al., Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol, 2018. 72(18): p. 2231-2264.
16. Byrne, R.A., et al., 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal, 2023. 44(38): p. 3720-3826.
17. Neumann, J.T., et al., Discrimination of patients with type 2 myocardial infarction. Eur Heart J, 2017. 38(47): p. 3514-3520.
18. Nestelberger, T., et al., Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction. J Am Coll Cardiol, 2017. 70(13): p. 1558-1568.
19. Chapman, A.R., et al., Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury. Circulation, 2018. 137(12): p. 1236-1245.
20. Ibanez, B., et al., 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2018. 39(2): p. 119-177.
21. Diercks, D.B., et al., Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol, 2006. 97(4): p. 437-42.
22. Reichlin, T., et al., Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med, 2012. 125(12): p. 1205-1213 e1.
23. Neumann, J.T., et al., Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med, 2019. 380(26): p. 2529-2540.
24. Neumann, J.T., et al., Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiol, 2016. 1(4): p. 397-404.
25. Koechlin, L., et al., Performance of the ESC 0/2h-algorithm using high-sensitivity cardiac troponin I in the early diagnosis of myocardial infarction. Am Heart J, 2021. 242: p. 132-137.
26. Stewart, R.A.H., et al., High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial. BMJ, 2021. 372: p. n355.
27. Hofmann, R., et al., Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med, 2017. 377(13): p. 1240-1249.
28. Henrikson, C.A., et al., Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med, 2003. 139(12): p. 979-86.
29. Charpentier, S., et al., Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: open-label, cluster-randomized, non-inferiority study. Scand J Trauma Resusc Emerg Med, 2020. 28(1): p. 36.
30. Roolvink, V., et al., Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol, 2016. 67(23): p. 2705-2715.
31. Pizarro, G., et al., Long-Term Benefit of Early Pre-Reperfusion Metoprolol Administration in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014. 63(22): p. 2356-2362.
32. Ibanez, B., et al., Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation, 2013. 128(14): p. 1495-503.
33. Chatterjee, S., et al., Early intravenous beta-blockers in patients with acute coronary syndrome—A meta-analysis of randomized trials. International Journal of Cardiology, 2013. 168(2): p. 915-921.
34. Morrison, L.J., et al., Mortality and Prehospital Thrombolysis for Acute Myocardial Infarction. Jama, 2000. 283(20).
35. Keeley, E.C., J.A. Boura, and C.L. Grines, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 2003. 361(9351): p. 13-20.
36. Oler, A., Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina. Jama, 1996. 276(10).
37. Eikelboom, J.W., et al., Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. The Lancet, 2000. 355(9219): p. 1936-1942.
38. Collet, J.P., et al., 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2021. 42(14): p. 1289-1367.
39. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Bmj, 1994. 308(6921): p. 81-106.
40. Montalescot, G., et al., Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med, 2014. 371(11): p. 1016-27.
41. Urban, P., et al., Defining high bleeding risk in patients undergoing percutaneous coronary
intervention: a consensus document from the Academic Research Consortium for High Bleeding
Risk. European Heart Journal, 2019. 40(31): p. 2632-2653.
42. Husted, S., et al., Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes, 2012. 5(5): p. 680-8.
43. Gimbel, M., et al., Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet, 2020. 395(10233): p. 1374-1381.
44. Schupke, S., et al., Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2019. 381(16): p. 1524-1534.
45. Kite, T.A., et al., Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J, 2022. 43(33): p. 3148-3161.
46. Le May, M.R., et al., Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol, 2005. 46(3): p. 417-24.
47. Fazel, R., et al., Comparison of Reperfusion Strategies for ST-Segment-Elevation Myocardial Infarction: A Multivariate Network Meta-analysis. J Am Heart Assoc, 2020. 9(12): p. e015186.
48. Di Mario, C., et al., Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet, 2008. 371(9612): p. 559-68.
49. Cantor, W.J., et al., Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. New England Journal of Medicine, 2009. 360(26): p. 2705-2718.
50. Pinto, D.S., et al., Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation, 2006. 114(19): p. 2019-25.
51. Pinto, D.S., et al., Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation, 2011. 124(23): p. 2512-21.
52. Richards, S.H., et al., Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol, 2018. 25(3): p. 247-259.
53. Delgado-Lista, J., et al., Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet, 2022. 399(10338): p. 1876-1885.
54. Critchley, J.A. and S. Capewell, Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA, 2003. 290(1): p. 86-97.
55. Chow, C.K., et al., Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation, 2010. 121(6): p. 750-8.
56. Frederix, I., P. Dendale, and J.P. Schmid, Who needs secondary prevention? Eur J Prev Cardiol, 2017. 24(3_suppl): p. 8-13.
57. Ambrosetti, M., et al., Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol, 2021. 28(5): p. 460-495.
58. Abreu, A., et al., Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol, 2021. 28(5): p. 496-509.
59. De Bacquer, D., et al., Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. Eur J Prev Cardiol, 2022. 29(2): p. 383-395.
60. Benzer, W., et al., Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. Int J Cardiol, 2017. 228: p. 58-67.
61. Ference, B.A., et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2017. 38(32): p. 2459-2472.
62. Mach, F., et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020. 41(1): p. 111-188.
63. Gencer, B., et al., Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol, 2020. 5(8): p. 952-957.
64. McDonagh, T.A., et al., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021. 42(36): p. 3599-3726.
65. Dahl Aarvik, M., et al., Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother, 2019. 5(1): p. 12-20.
66. Pfeffer, M.A., et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 1992. 327(10): p. 669-77.
67. Investigators, T.A.S., Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Lancet, 1993. 342(8875).
68. Heart Outcomes Prevention Evaluation Study, I., et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 2000. 342(3): p. 145-53.
69. Group, A.I.M.I.C., Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation, 1998. 97(22): p. 2202-12.
70. Pitt, B., et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003. 348(14): p. 1309-21.
71. Yedlapati, S.H., et al., Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2021. 10(6): p. e019636.
72. Liprandi, A.S., et al., Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation. Glob Heart, 2021. 16(1): p. 55.
73. Phrommintikul, A., et al., Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J, 2011. 32(14): p. 1730-5.
74. Organization, W.H., Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. 2024.
75. Moghaddam, N., et al., Association of Anemia With Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv, 2018. 11(12): p. e007175.
76. Herold, G., Innere Medizin 2022.
77. Czempik, P.F., et al., Hospital-Acquired Anemia in Patients Hospitalized in the Intensive Care Unit: A Retrospective Cohort Study. J Clin Med, 2022. 11(14).
78. Carson, J.L., et al., Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet, 1996. 348(9034): p. 1055-60.
79. Anand, I., et al., Anemia and its relationship to clinical outcome in heart failure. Circulation, 2004. 110(2): p. 149-54.
80. Sarnak, M.J., et al., Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol, 2002. 40(1): p. 27-33.
81. Jung, C., et al., The role of anemia on admission in acute coronary syndrome - An umbrella review of systematic reviews and meta-analyses. Int J Cardiol, 2022. 367: p. 1-10.
82. Salisbury, A.C., et al., Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes, 2010. 3(4): p. 337-46.
83. Sabatine, M.S., et al., Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation, 2005. 111(16): p. 2042-9.
84. Anker, S.D., et al., Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J, 2009. 30(11): p. 1331-9.
85. Mamas, M.A., et al., Relationship Between Anemia and Mortality Outcomes in a National Acute Coronary Syndrome Cohort: Insights From the UK Myocardial Ischemia National Audit Project Registry. J Am Heart Assoc, 2016. 5(11).
86. Wester, A., et al., Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial. J Am Heart Assoc, 2019. 8(16): p. e012741.
87. Dauerman, H.L., et al., Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol, 2005. 96(10): p. 1379-83.
88. Lipsic, E., et al., Hemoglobin levels and 30-day mortality in patients after myocardial infarction. Int J Cardiol, 2005. 100(2): p. 289-92.
89. Wischmann, P., et al., Anaemia is associated with severe RBC dysfunction and a reduced circulating NO pool: vascular and cardiac eNOS are crucial for the adaptation to anaemia. Basic Res Cardiol, 2020. 115(4): p. 43.
90. Zindrou, D., K.M. Taylor, and J.P. Bagger, Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet, 2002. 359(9319): p. 1747-8.
91. McKechnie, R.S., et al., Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation, 2004. 110(3): p. 271-7.
92. Habib, S. and A. Ali, Biochemistry of nitric oxide. Indian J Clin Biochem, 2011. 26(1): p. 3-17.
93. Silbernagl, ed. Physiologie. 7. ed. 2014
94. Dhananjayan, R., et al., Endothelial Dysfunction in Type 2 Diabetes Mellitus. Indian J Clin Biochem, 2016. 31(4): p. 372-9.
95. Gordge, M.P., How cytotoxic is nitric oxide? Exp Nephrol, 1998. 6(1): p. 12-6.
96. Moncada, S., R.M. Palmer, and E.A. Higgs, Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev, 1991. 43(2): p. 109-42.
97. Wood, K.C., et al., Circulating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis. Arterioscler Thromb Vasc Biol, 2013. 33(8): p. 1861-71.
98. Ford, P.C., D.A. Wink, and D.M. Stanbury, Autoxidation kinetics of aqueous nitric oxide. FEBS Lett, 1993. 326(1-3): p. 1-3.
99. Kleinbongard, P., et al., Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med, 2006. 40(2): p. 295-302.
100. Rhodes, P., et al., The L-arginine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun, 1995. 209(2): p. 590-6.
101. Lauer, T., et al., Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A, 2001. 98(22): p. 12814-9.
102. Dejam, A., et al., Emerging role of nitrite in human biology. Blood Cells Mol Dis, 2004. 32(3): p. 423-9.
103. Doyle, M.P. and J.W. Hoekstra, Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem, 1981. 14(4): p. 351-8.
104. Malte Kelm*, H.P.-S., Michael Preik, Bodo E. Strauer, | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 01.10.2026 | |||||||
| Dateien geändert am: | 01.10.2026 | |||||||
| Promotionsantrag am: | 04.03.2026 | |||||||
| Datum der Promotion: | 01.10.2026 |
